A5023734910- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Cardiovascular Function and Risk Factors
- Cardiovascular and exercise physiology
- Diet and metabolism studies
- Adipokines, Inflammation, and Metabolic Diseases
- Pharmacology and Obesity Treatment
- Heart Rate Variability and Autonomic Control
- Blood Pressure and Hypertension Studies
- Pancreatic function and diabetes
- Cardiac Health and Mental Health
- Hormonal Regulation and Hypertension
- Heart rate and cardiovascular health
- Fatty Acid Research and Health
- Diet, Metabolism, and Disease
- Hormonal and reproductive studies
- Heart Failure Treatment and Management
- Adipose Tissue and Metabolism
Amager Hospital
2014-2021
Copenhagen University Hospital
2014-2019
Glostrup Hospital
2018-2019
University of Copenhagen
2015-2019
Bispebjerg Hospital
2014-2017
Hvidovre Hospital
2014
Abstract Background Dyslipidaemia and low-grade inflammation are central in atherogenesis linked to overweight physical inactivity. Lifestyle changes important secondary prevention of coronary artery disease (CAD). We compared the effects combined weight loss interval training with alone on fitness, body composition, dyslipidaemia overweight, sedentary participants CAD. Methods Seventy CAD patients, BMI 28–40 kg/m 2 age 45–75 years were randomised (1) 12 weeks’ aerobic (AIT) at 90% peak...
OBJECTIVE Reduced heart rate variability (HRV) and increased (HR) have been associated with cardiovascular mortality. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increase HR, studies suggested that they may reduce HRV. We examined the effect of GLP-1 RA liraglutide on HRV diurnal variation HR in overweight patients newly diagnosed type 2 diabetes (T2D) stable coronary artery disease (CAD). RESEARCH DESIGN AND METHODS Liraglutide or placebo was administrated to a backbone therapy...
Patients with type 2 diabetes (T2D) and coronary artery disease (CAD) have increased risk of cardiac dysfunction. The diabetic heart is characterized by fatty acid oxidation reduced glucose uptake resulting in efficiency. Glucagon-like peptide-1 (GLP-1) has shown to increase myocardial improve function. We examined the effect GLP-1 receptor agonist, liraglutide, on systolic function left ventricle (LV) patients T2D stable CAD. In this placebo-controlled crossover study, 41 subjects CAD were...
The glucagon-like peptide-1 receptor agonist liraglutide has been shown to reduce blood pressure (BP) in clinical trials using office BP measurements. However, the effects of on 24-h and diurnal variation have not explored sufficiently.Forty-one patients with type 2 diabetes stable coronary artery disease were randomized receive or placebo a backbone therapy metformin this double-blind, placebo-controlled 12 along weeks crossover study. Ambulatory monitoring (ABPM) was performed at start end...
Diastolic dysfunction is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and associated overweight, glucose dysregulation coronary artery disease (CAD). The GLP-1 receptor agonist, liraglutide, has shown to induce weight loss improve metabolic factors, thus modulating factors diastolic dysfunction. We have previously reported the effects of liraglutide on systolic function, this current study we explore function parameters stable CAD, preserved left ventricular ejection...
Newly diagnosed type 2 diabetes mellitus (T2DM) in patients with coronary artery disease (CAD) more than doubles the risk of death compared otherwise matched glucose tolerant patients. The biguanide metformin is drug choice treatment T2DM and has shown to ameliorate cardiovascular morbidity myocardial infarction (MI). incretin hormone, glucagon-like peptide-1 (GLP-1) improves β-cell function, insulin sensitivity causes weight loss been suggested have beneficial effects on cardiac function....
Aims The aims of the study were to investigate effects GLP ‐1 receptor agonist liraglutide as add‐on metformin on insulin sensitivity ( S i) and glucose effectiveness g) in addition its positive beta‐cell function overweight/obese patients with coronary artery disease CAD ) type 2 diabetes mellitus T2DM ). Methods design was a randomized, double‐blind, placebo‐controlled, cross‐over trial stable newly diagnosed well‐controlled . Patients treated liraglutide/metformin vs placebo/metformin for...
Abstract Elevated levels of non‐esterified fatty acids (NEFA) play a role in insulin resistance, impaired beta‐cell function and they are denominator the abnormal atherogenic lipid profile that characterizes obese patients with type 2 diabetes (T2DM). We hypothesized GLP‐1 receptor agonist liraglutide, combination metformin, would reduce lipolysis. In randomized, double‐blind, placebo‐controlled, cross‐over trial, 41 T2DM coronary artery disease were randomized treated liraglutide‐metformin...
Abstract Background Hyperinsulinemia aggravates insulin resistance and cardio-vascular disease. How the insulinotropic glucagon-like peptide-1 receptor agonist liraglutide in a physiologic post-prandial setting may act on pancreatic alpha beta-cell function patients with coronary artery disease (CAD) type 2 diabetes (T2DM) is less clear. Methods Insulin resistant established CAD newly diagnosed well-controlled T2DM were recruited to placebo-controlled, cross-over trial two treatment periods...
Postprandial non-esterified fatty acid (NEFA) and triglyceride (TG) responses are increased in subjects with type 2 diabetes mellitus (T2DM) may impair insulin action increase risk of cardiovascular disease death. Dietary carbohydrate reduction has been suggested as non-pharmacological therapy for T2DM, but the acute effects on NEFA TG during subsequent meals remain to be investigated. were assessed T2DM by comparing a carbohydrate-reduced high-protein (CRHP) diet conventional (CD) an...
Aims: To evaluate in a real-word routine-care practice the effect of liraglutide as add-on treatment type 2 diabetic patients treated with oral antidiabetic agents and/or insulin. Methods: A retrospective study from 3 outpatient clinics Copenhagen, Denmark, all (n = 534) initiating liraglutide. 346 were ≥3 months. Excluded analysis were: 107 changing exenatide and 83 due to lack clinical response or adverse events. Results: In 149 was agents, most often metformin plus sulfonylurea 86). Mean...
Objective: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown to reduce blood pressure in some clinical trials. Only a few studies examined the effect of GLP-1 RAs on 24-h variation pressure. In this study, we explored RA liraglutide and heart rate (HR) patients with type 2 diabetes (T2DM) coronary artery disease (CAD).Design method: Forty-one subjects were randomized plus metformin or placebo double-blind, placebo-controlled 12 weeks cross-over study. Subjects underwent...